IN THE NEWS
HIV, hepatitis scare may affect 40,000 US clinic patients
Clean needle program gets thumbs-up
Grapefruit compound may help combat hepatitis C infection
More support for multi-dose syringe ban
Migenix amends protocol in hepatitis C study
Sustained response to hepatitis C treatment lowers liver complications and death in HIV/HCV coinfected people
Intercell´s therapeutic hepatitis C vaccine meets primary endpoints in Phase II
New bid for hepatitis C vaccine
OctoPlus to begin Phase IIa study of hepatitis C drug Locteron in US
Schering-Plough, OraSure Tech collaborate on oral hepatitis C test outside U.S.
SciClone says hepatitis C drug trial's interim data promising
Presidio Pharmaceuticals and Numerate announce research collaboration to identify improved hepatitis C therapeutics
Husband blast on Anita's bug
1,000 people living with killer disease
Amarillo Bioscience partner, CytoPharm, to conduct 144 patient phase 2 hepatitis C trial in Taiwan
Travel risk of hepatitis ignored
Lack of inmate treatment costs state $8M in lawsuit; four prisoners each receive $2M
Old, dirty jail razors raise fears of hep C; used blades erroneously given back to inmates to shave with
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES
Inferior response of Asian vs. non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. Freshwater DA, et al. J Viral Hepat. 2008 Feb;15(2):115-9.
Novel controlled-release lemna-derived IFN-alpha2b (Locteron): Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. De Leede LG, et al. J Interferon Cytokine Res. 2008 Feb;28(2):113-22.
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Takaki S, et al. Intervirology. 2007;50(6):439-46. Epub 2008 Feb 4.
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. Furusyo N, et al. J Gastroenterol Hepatol. 2008 Feb 1 [Epub ahead of print]
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Lindsay KL, et al. Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41.
The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the HALT-C trial. Everson GT, et al. Aliment Pharmacol Ther. 2008 Feb 7 [Epub ahead of print]
Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology center. Evon DM, et al. Aliment Pharmacol Ther. 2008 Feb 7 [Epub ahead of print]
The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. Mosley JW, et al. J Viral Hepat. 2008 Feb;15(2):120-8.
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. Reddy KR, et al. J Viral Hepat. 2008 Feb;15(2):129-36.
Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. Lemos LB, et al. J Clin Gastroenterol. 2008 Feb;42(2):208-11.
Hepatitis C virus infection and interferon therapy in patients with Down syndrome. Miyoshi Y, et al. Pediatr Int. 2008 Feb;50(1):7-11.
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Landau DA, et al. Arthritis Rheum. 2008 Feb;58(2):604-11.
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Delgado-Borrego A, et al. Liver Transpl. 2008 Feb;14(2):193-201.
Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Spinelli JJ, et al. Int J Cancer. 2008 Feb 1;122(3):630-3.
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. Tarantino G, et al. J Viral Hepat. 2008 Feb 5 [Epub ahead of print]
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? Torre F, et al. Dig Liver Dis. 2008 Feb 20 [Epub ahead of print]
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Majer M, et al. Brain Behav Immun. 2008 Feb 5 [Epub ahead of print]
Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. Fujimoto T, et al. J Gastroenterol Hepatol. 2008 Feb 1 [Epub ahead of print]
Hepatitis C virus receptor expression in normal and diseased liver tissue. Reynolds GM, et al. Hepatology. 2008 Feb;47(2):418-27.
Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. Gigi E, et al. J Viral Hepat. 2008 Feb;15(2):145-54.
Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C. Kumar D, et al. World J Gastroenterol. 2008 Feb 7;14(5):701-8.
Neuroactive steroids and fatigue severity in patients with primary biliary cirrhosis and hepatitis C. Ahboucha S, et al. Neurogastroenterol Motil. 2008 Feb 13 [Epub ahead of print]
Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. Nakamura M, et al. J Med Virol. 2008 Apr;80(4):632-9.
Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment. Di Lello F, et al. J Med Virol. 2008 Apr;80(4):619-27.
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. Fishman SL, et al. J Infect Dis. 2008 Feb 15;197(4):597-607.
Endogenous interferon-alpha level is increased in hepatitis C virus (HCV)-positive pregnant women. Paternoster DM, et al. J Clin Gastroenterol. 2008 Feb;42(2):204-7.
Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. Tien PC, et al. J Acquir Immune Defic Syndr. 2008 Feb 14 [Epub ahead of print]
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Duclos-Vallée JC, et al. Hepatology. 2008 Feb;47(2):407-17.
Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. Operskalski EA, et al. J Clin Virol. 2008 Feb 1 [Epub ahead of print]
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. Smit C, et al. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5.
COMPLEMENTARY & ALTERNATIVE THERAPY
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Seeff LB, et al. Hepatology. 2008 Feb;47(2):605-12.
Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Overbeck S, Rink L, Haase H. Arch Immunol Ther Exp (Warsz). 2008 Jan-Feb;56(1):15-30. Epub 2008 Feb 5.
Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. Pittaluga F, et al. J Med Virol. 2008 Feb;80(2):254-60.
Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Patel K, et al. Clin Gastroenterol Hepatol. 2008 Feb;6(2):242-7. Epub 2008 Jan 9.
High diagnostic accuracy of antigen microarray for sensitive detection of hepatitis C virus infection. Kwon JA, et al. Clin Chem. 2008 Feb;54(2):424-8.
Sensitivity of a rapid immuno-chromatographic test for Hepatitis C antibodies detection. Desbois D, et al. J Clin Virol. 2008 Feb;41(2):129-33.
Nosocomial hepatitis C in a thoracic surgery unit; retrospective findings generating a prospective study. Cardell K, et al. J Hosp Infect. 2008 Feb 20 [Epub ahead of print]
Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice?Cheung RC, et al. J Clin Gastroenterol. 2008 Feb 15 [Epub ahead of print]
How Physicians Describe Outcomes to HCV Therapy: Prevalence and Meaning of "Cure" During Provider-Patient In-office Discussions of HCV. Hamilton HE, et al. J Clin Gastroenterol. 2008 Feb 13 [Epub ahead of print]
Health-related quality of life in children with hepatitis C acquired in the first year of life. Nydegger A, et al. J Gastroenterol Hepatol. 2008 Feb;23(2):226-30.
C is the most common, chronic blood-borne